The Trump Administration recently issued two executive orders relating to biomedical science. The first involved the regulation of biotechnology products; the second involved transparency in healthcare costs. We believe both are a step in the right direction.
As part of regulatory reform, and given the increasing use of computer algorithms in patient care, the Food and Drug Administration released draft guidelines for software use that aids both doctors and their patients.
Yesterday, ACSH s Ariel Savransky attended the 2nd Annual E-cig conference in New York City. Conference attendees included investors, industry leaders and public health and regulatory experts and discussion was
Dr. Gilbert Ross in The American, May 14, 2014. At last, after months